|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/13/20 Acelrx Pharmaceuticals Inc 8-K:2,8,9 1/13/20 2:57K RDG Filings/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 16K 2: EX-99.1 Miscellaneous Exhibit HTML 17K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2020
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
41-2193603 |
|||
|
(State of Incorporation) |
(Commission File No.) |
(I.R.S. Employer Identification No.) |
351 Galveston Drive
Redwood City, CA 94063
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 216-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common Stock, $0.001 par value |
ACRX |
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
ITEM 2.02 |
Results of Operations and Financial Condition |
On January 13, 2020, AcelRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a business update, expected total revenues of $2.3 million for 2019 and $66.1 million in cash, cash equivalents and short-term investments as of December 31, 2019 (the “Release”). A copy of the Release is furnished herewith as Exhibit 99.1.
The Company has not yet completed its year-end financial close process for the year ended December 31, 2019 and these estimates for total revenues and cash, cash equivalents and short-term investments are based on preliminary estimates of the Company’s financial results that it expects to report for the applicable periods. These estimates are subject to change upon completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm, OUM & Co. LLP, has not audited, reviewed or compiled these estimates and, accordingly, does not express an opinion on, or provided any other form of assurance with respect to, these preliminary estimates. These estimates are not a comprehensive statement of the Company’s financial results for the year ended December 31, 2019 and its actual results may differ materially from these estimates as a result of the completion of the Company’s financial closing procedures, final adjustments and other developments arising between now and the time that our financial results for this period are finalized.
|
ITEM 8.01 |
Other Events |
The information contained in Item 2.02 above and the Release are incorporated herein by reference.
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS. |
|
(d) |
Exhibits. |
|
Exhibit Number |
|
Description |
|
99.1 |
||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
acelrx pharmaceuticals, inc. |
||
|
Date: January 13, 2020 |
|
By: |
/s/ Raffi Asadorian |
|
|
|||
|
|
Chief Financial Officer |
||
3.
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 1/13/20 | None on these Dates | ||
| 12/31/19 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/28/22 Acelrx Pharmaceuticals Inc. 424B5 1:488K RDG Filings/FA 11/15/21 Acelrx Pharmaceuticals Inc. 424B5 1:461K RDG Filings/FA 1/21/21 Acelrx Pharmaceuticals Inc. 424B5 1:515K RDG Filings/FA 1/19/21 Acelrx Pharmaceuticals Inc. 424B5 1:534K RDG Filings/FA 12/10/20 Acelrx Pharmaceuticals Inc. 424B5 1:436K RDG Filings/FA |